2009 Aug 15;616(1-3):16-21. doi: 10.1016/j.ejphar.2009.06.004. Epub 2009 Jun 17.
The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi’s sarcoma cells in vitro.
Abstract
![pm1](/wp-content/uploads/2013/04/Pub-Med-e1423848464246.jpg)
- PMID:
- 19539619
- [PubMed – indexed for MEDLINE]
-
Publication Types, MeSH Terms, Substances
Publication Types
MeSH Terms
- Animals
- Antineoplastic Agents/pharmacology
- Benzoxazines/pharmacology*
- Cannabinoids/pharmacology
- Caspases/metabolism
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Cell Survival/drug effects
- Enzyme Activation/drug effects
- Female
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Mitogen-Activated Protein Kinases/metabolism
- Morpholines/pharmacology*
- Naphthalenes/pharmacology*
- Pregnancy
- Receptor, Cannabinoid, CB1/agonists*
- Receptor, Cannabinoid, CB1/antagonists & inhibitors
- Receptor, Cannabinoid, CB1/genetics
- Receptor, Cannabinoid, CB2/agonists*
- Receptor, Cannabinoid, CB2/antagonists & inhibitors
- Receptor, Cannabinoid, CB2/genetics
- Sarcoma, Kaposi/genetics
- Sarcoma, Kaposi/metabolism
- Sarcoma, Kaposi/pathology*
- Substrate Specificity
Substances
LinkOut – more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous